Switching therapy from natalizumab to fingolimod in relapsing-remitting multiple sclerosis: clinical and magnetic resonance imaging findings.
about
Fingolimod for multiple sclerosis and emerging indications: appropriate patient selection, safety precautions, and special considerationsClinical efficacy, safety, and tolerability of fingolimod for the treatment of relapsing-remitting multiple sclerosisNeuroimmunotherapies Targeting T Cells: From Pathophysiology to Therapeutic Applications.Catastrophic outcome of patients with a rebound after Natalizumab treatment discontinuationMS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study.Efficacy and Safety of Fingolimod in Daily Practice: Experience of an Academic MS French CenterImmunological mechanism of action and clinical profile of disease-modifying treatments in multiple sclerosis.Treating multiple sclerosis with monoclonal antibodies: a 2013 update.Fingolimod in active multiple sclerosis: an impressive decrease in Gd-enhancing lesions.Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trialPML-IRIS during Fingolimod Diagnosed after Natalizumab DiscontinuationClinical and radiologic rebound after discontinuation of natalizumab therapy in a highly active multiple sclerosis patient was not halted by dimethyl-fumarate: a case report.Natalizumab Discontinuation and Treatment Strategies in Patients with Multiple Sclerosis (MS): A Retrospective Study from Two Italian MS Centers.Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis.Fingolimod after natalizumab and the risk of short-term relapse.Safety, tolerability, and efficacy of oral therapies for relapsing-remitting multiple sclerosis.Monoclonal antibodies in treatment of multiple sclerosis.Bridging, switching or drug holidays - how to treat a patient who stops natalizumab?Pharmacokinetic evaluation of fingolimod for the treatment of multiple sclerosis.Clinical management of multiple sclerosis and neuromyelitis optica with therapeutic monoclonal antibodies: approved therapies and emerging candidates.Fingolimod hydrochloride for the treatment of relapsing remitting multiple sclerosis.Disease activity return after natalizumab cessation in multiple sclerosis.Relapse frequency in transitioning from natalizumab to dimethyl fumarate: assessment of risk factors.Pulsed corticosteroid treatment in MS patients stabilizes disease activity following natalizumab withdrawal prior to switching to fingolimod.Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis.Disability Progression After Switching from Natalizumab to Fingolimod or Interferon Beta/Glatiramer Acetate Therapies: A NARCOMS Analysis.Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis.High discontinuation rate of natalizumab in JC virus seropositive patients due to significant anxiety and safety feelings.Pattern Recognition of the Multiple Sclerosis Syndrome.A longitudinal real-life comparison study of natalizumab and fingolimod.Reduction of the washout time between natalizumab and fingolimod.Observational Study of Switching from Natalizumab to Immunomodulatory Drugs.Long-term evaluation of NEDA-3 status in relapsing-remitting multiple sclerosis patients after switching from natalizumab to fingolimod
P2860
Q26765300-0BDE8940-593B-47E2-952D-23E062B6212CQ26771635-2C9BE726-D999-40BC-ABF7-EB5B73EE00D0Q30699740-F93FE40D-B4A9-42CA-B9D9-2D5B19495A80Q33562198-5D814C2E-719B-414E-8E11-A74A5BA00B8AQ33571905-4C76FAE1-50F8-45EB-BD42-5DEE50E0DDE8Q33639041-658821BC-ED9D-443C-B4CD-933FFE062AE7Q33755345-F31CB9FD-2F20-49D3-B4AB-CDBFFB16605FQ34330211-3B737BC3-6ACD-4044-88F7-9CFEFA494777Q34538811-286F29F6-ECE7-445C-B984-77DFEF5F2F3BQ34622205-6F2CBCD6-B82A-4C93-882C-6D97E48AB62EQ34650456-4FB6A586-DDF7-432F-98D6-526AFCEC4411Q35862875-50FCBD73-E578-46E1-8701-078910AF6678Q36389681-44867A91-93D9-4037-BC5A-57D3F96E3D8DQ36975701-5B92BB7A-E126-4C39-AD83-C0B59658D7BEQ37725909-D247F585-5460-4673-A325-40F0BF0773ABQ38117110-828CBCB7-BB0A-43F5-A40E-0988EB5538D3Q38133865-D40DDA27-58C1-4F09-A6FE-2B7EF9AC7877Q38152451-78E9F0DE-074D-4015-A2F0-6E454A40AF82Q38192006-BFAA98AB-AB97-43DE-B3EF-23C15DA5E4DDQ38286209-01D73984-721D-48C3-ADD3-B8F451FE9A30Q38606914-6EB41F91-86FC-42DD-9F18-D9B4DE19D708Q38779091-E64F5323-253F-4FBD-8022-104D96C4AB24Q40747927-8FFD9BF4-BCB6-4380-B0C6-96FAAA781947Q41002593-D6A39F26-2F60-4D75-9F98-2D8B51CD0D28Q41369754-B8B060EF-AE31-4465-BE85-7B3DF6DF122AQ41626879-3F5DA196-3271-4528-9896-E47D0DF1EAA9Q44840261-ACE79586-0E57-4365-8AC2-34DEECDC5EB3Q45347558-13E7A9C3-5A8B-46E7-AB69-54AC702C77E0Q47096340-9A1DC11E-A288-461F-B600-F41A1F18EDADQ48650575-92452AA8-7FD9-4A7A-A79C-6F889D3034F2Q50949572-160CFEE4-1412-4B8D-A742-F44CF35EFF8BQ51218322-E6DEFDD0-744D-43A5-A3A2-6EACF54E786FQ58793277-94831C4A-357E-4C46-9026-0423C849388F
P2860
Switching therapy from natalizumab to fingolimod in relapsing-remitting multiple sclerosis: clinical and magnetic resonance imaging findings.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Switching therapy from nataliz ...... ic resonance imaging findings.
@en
Switching therapy from nataliz ...... ic resonance imaging findings.
@nl
type
label
Switching therapy from nataliz ...... ic resonance imaging findings.
@en
Switching therapy from nataliz ...... ic resonance imaging findings.
@nl
prefLabel
Switching therapy from nataliz ...... ic resonance imaging findings.
@en
Switching therapy from nataliz ...... ic resonance imaging findings.
@nl
P2093
P356
P1476
Switching therapy from nataliz ...... tic resonance imaging findings
@en
P2093
P304
P356
10.1177/1352458512464282
P50
P577
2012-11-01T00:00:00Z